ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2017-039]

Apixaban For the Reduction Of Thrombo-Embolism In Patients With Device-Detected Sub-Clinical Atrial Fibrillation (Artesia)

The purpose of this study is to determine which treatment is best for preventing stroke or systemic embolism in patients who have experienced at least one episode of Sub clinical Atrial Fibrillation detected by their pacemaker, ICD or ICM and also have other risk factors for stroke.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-1256